Activity Overview
Please read the following information about this continuing pharmacy education (CPE) activity before accessing the presentation using links located at the bottom of this page.
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides 1 hour (0.1 CEU) of continuing pharmacy education credit (ACPE activity #204-000-11-410-H01P).
Methods and Format
This is an online activity consisting of audio and slides for one presentation, a post-test, and an activity evaluation tool. Participants should claim continuing education credit for this internet-based educational activity only if they have not claimed credit for the live activity. Participants must view the presentation, take the activity post-test, and complete the course evaluation to receive continuing pharmacy education credit. A minimum score of 70% is required on the test for credit to be awarded, and participants may print their official statements of continuing pharmacy education credit immediately. The estimated time to complete this activity is 1 hour. This activity is provided free of charge.
Target Audience
This continuing pharmacy education activity was planned to meet the needs of all pharmacists, especially those interested in new and emerging antithrombotic agents to help reduce or prevent stroke in patients with atrial fibrillation.
Activity Content
Current challenges associated with using antithrombotic therapy for stroke prevention in patients with atrial fibrillation (AF) will be highlighted in this presentation. Such challenges include the underuse of anticoagulation therapy and limitations of methods for assessing bleeding risk and stroke risk in this patient population. A new oral direct thrombin inhibitor was recently approved for preventing stroke in patients with AF, and several other antithrombotic agents are in late stages of development and clinical trials. These new and emerging agents provide new therapeutic options for preventing stroke in patients with AF as well as opportunities for pharmacists managing these patients in both inpatient and outpatient settings. Key data from recent trials describing the efficacy and safety of these antithrombotic agents for stroke prevention in AF will be summarized. The presentation will also explore the pharmacist's potential role in selecting antithrombotic drug therapy and monitoring potential drug interactions associated with these agents to ensure their safe and effective use. Other important roles that pharmacists can play in guiding formulary decisions, developing treatment guidelines, and ensuring continuity of care will be discussed. A patient case will be incorporated to illustrate decision-making processes in reviewing the risks and benefits of using antithrombotic therapies for stroke prevention in patients with AF.
Learning Objectives
After participating in this knowledge-based CPE activity, participants should be able to
- List two sources of evidence-based guidelines related to preventing stroke in patients with atrial fibrillation.
- Identify at least two current challenges related to antithrombotic therapy in patients with atrial fibrillation.
- List the major findings of at least three clinical trials involving the use of new and emerging antithrombotic agents to prevent stroke in patients with atrial fibrillation.
- List at least two potential roles for pharmacists related to ensuring the safe and effective use of new and emerging antithrombotic agents for preventing stroke in patients with AF at both the patient-care and institutional levels.
- Identify relevant patient characteristics to guide the selection and monitoring of antithrombotic therapy in patients with atrial fibrillation.
Faculty
Toby C. Trujillo, Pharm.D., BCPS (AQ Cardiology)Associate Professor
University of Colorado Denver School of Pharmacy
Clinical Specialist – Cardiology/Anticoagulation
University of Colorado Hospital
Aurora, Colorado
Toby C. Trujillo, Pharm.D., BCPS (AQ Cardiology), is Associate Professor of Clinical Pharmacy at the University of Colorado Denver School of Pharmacy in Aurora, Colorado. He also serves as Clinical Specialist in cardiovascular pharmacotherapy and anticoagulation at University of Colorado Hospital.
Dr. Trujillo earned his Bachelor of Science degree in biochemistry from the University of California, Davis and his Doctor of Pharmacy degree from the University of California, San Francisco, where he also completed a residency in pharmacy practice. Dr. Trujillo completed a fellowship in cardiovascular pharmacotherapy at The University of Arizona, and he is a board-certified pharmacotherapy specialist with added qualifications in cardiology.
Dr. Trujillo's current responsibilities at University of Colorado Hospital include providing clinical pharmacy services to cardiology, as well as directing the inpatient anticoagulation program. He also serves as co-chair of the anticoagulation subcommittee of the P&T committee. Dr. Trujillo currently serves as a preceptor to both pharmacy students and residents. His lectures at the School of Pharmacy focus on ischemic heart disease, antithrombotic therapy, and other cardiology and critical care topics.
Within the American Heart Association, Dr. Trujillo is a member of the Clinical Pharmacology Committee, which resides under the Council on Clinical Cardiology. He has also served on a number of committees within the American College of Clinical Pharmacy, served as a speaker on numerous occasions on a national level, and authored several articles and book chapters in the area of cardiovascular pharmacotherapy. Dr. Trujillo is a member of the American Society of Health-System Pharmacists, and he helped develop current standards for postgraduate year 2 (PGY2) cardiology residency training programs.
Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Guidelines for Standards for Commercial Support, ASHP Advantage requires that all individuals who have control in planning or presenting educational content disclose all relevant financial relationships with any commercial interest. This includes faculty, teachers, authors, activity directors, and members of planning committees. An individual has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on presentations.
All faculty and planners for ASHP Advantage education activities are qualified and selected by ASHP Advantage and required to disclose any relevant financial relationships with commercial interests. ASHP Advantage identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity.
The faculty and planners report the following relationships:
Toby C. Trujillo, Pharm.D., BCPS (AQ Cardiology), Faculty
Dr. Trujillo is on the speakers bureau for sanofi-aventis.
Cynthia A. Sanoski, Pharm.D., FCCP, BCPS, Initiative Chair and Faculty
Dr. Sanoski declares that she has no relationships pertinent to this activity.
Nancy L. Shapiro, Pharm.D., FCCP, BCPS, Faculty
Dr. Shapiro declares that she has no relationships pertinent to this activity.
Ron DeChant, M.S., B.S.Pharm., ASHP Advantage Staff
Mr. DeChant declares that he has no relationships pertinent to this activity.
This activity is supported by educational grants from Bristol-Myers Squibb and Pfizer, Inc.
Launch Presentation*
Preventing Stroke in Atrial Fibrillation: Overview of New and Emerging Antithrombotic Agents and Roles for Pharmacists(60 minutes)
Toby C. Trujillo, Pharm.D., BCPS (AQ Cardiology)
*Allow additional time to complete the post-test and evaluation.
Download Post-Test
Print the post-test for your reference. Please note that to be eligible for continuing pharmacy education credit, you must go to the ASHP CE Center and complete the test online.
Planned and coordinated by ASHP Advantage
